RNA

Avidity Biosciences, Inc.

39.65 USD
+0.01 (+0.03%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avidity Biosciences, Inc. stock is up 34.41% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 4 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
12 Jun 14:00 21 Jun, 2024 35.00 CALL 90 2215
12 Jun 14:01 21 Jun, 2024 35.00 CALL 600 2215
12 Jun 15:48 21 Jun, 2024 30.00 CALL 80 2455
12 Jun 18:37 21 Jun, 2024 35.00 CALL 1000 2215
13 Jun 18:22 21 Jun, 2024 26.00 CALL 22 45
13 Jun 18:59 21 Jun, 2024 25.00 CALL 144 153
13 Jun 19:40 20 Sep, 2024 30.00 CALL 50 74
14 Jun 13:32 21 Jun, 2024 24.00 CALL 145 145
14 Jun 15:37 20 Sep, 2024 32.00 PUT 126 301
14 Jun 19:26 21 Jun, 2024 30.00 CALL 101 2318

About Avidity Biosciences, Inc.

Avidity Biosciences, Inc. engages in the development of oligonucleotide-based therapies. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the. treatment of Duchenne Muscular Dystrophy.

  • Bank of America
    Thu Jun 13, 12:08
    buy
    confirm
  • Needham
    Mon Jun 10, 06:58
    buy
    confirm